Last Updated: June 25, 2026

Patent: 12,104,184


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 12,104,184
Title:PH20 polypeptide variants, formulations and uses thereof
Abstract:Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
Inventor(s):Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Assignee: Halozyme Inc , Halozyme Therapeutics Inc
Application Number:US18/068,443
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 12,104,184: Claims, Scope, and US Landscape Impact

United States Patent 12,104,184 (US 12,104,184) is a granted US patent with enforceable claims that can support exclusion and licensing leverage for the defined subject matter. A complete claim-by-claim technical and legal analysis requires the exact claim text and specification-supported claim constructions. No claim text, figure references, priority data, assignee, inventors, or International Patent Classification (IPC/CPC) data is provided in the prompt, and the patent number alone is insufficient to reliably reproduce the claims without a source document. Under the operating constraints, an incomplete or potentially incorrect analysis is not produced.

What is US 12,104,184’s enforceable claim scope?

A claim scope analysis is not provided because the operative claims (independent and dependent) are not supplied, and no external text is available in the prompt to ground term definitions and limitations to the specification.

How broad are the independent claims versus dependent claim fallbacks?

No analysis is provided because it requires the independent claim language, dependent claim dependencies, and the specification’s support for each limitation. Without the claim set, any breadth or fallback characterization risks inaccuracy.

What are the key claim limitations that determine infringement and design-around risk?

No analysis is provided for the same reason: infringement turns on exact limitations (structural elements, functional steps, performance ranges, selection criteria, process order, and optionality). Without claim text, term-level parsing cannot be done.

What is the US patent landscape around US 12,104,184 (family, continuations, and related filings)?

No landscape analysis is provided because it requires at minimum: application publication number(s), priority dates, family members, assignee and inventors, and CPC/IPC classification. Without these, novelty, obviousness risk, and non-obviousness-critical distinctions cannot be assessed.

What prior art most threatens patentability or validity (anticipation/obviousness)?

No validity analysis is provided because it requires identified prior art references mapped to each claim limitation and a formal anticipation/obviousness matrix. The prompt includes no citation candidates or claim elements.

Where are the freedom-to-operate fault lines (direct infringement, induced infringement, and contributory infringement)?

No FTO risk analysis is provided because it requires:

  • claim elements tied to specific product features/process steps,
  • interpretation of “comprising/consisting” transitions,
  • knowledge and intent standards for inducement/contribution,
  • and the presence of all asserted limitations in competitor products or processes.

Are there common design-around routes if competitors avoid specific limitations?

No design-around routes are provided because they depend on the exact limiting features and their disclosure in the specification. Without claim language, the analysis cannot target likely avoidance strategies.

What does the claims-to-practice timeline imply for licensing strategy?

No timeline or enforcement strategy is provided because it requires filing dates, prosecution history, claim amendments, and potential reexamination or post-grant events. None is provided.


Key Takeaways

  • No claim-by-claim or landscape analysis is produced because the prompt does not include the operative claim text, specification context, bibliographic data, or related publication identifiers needed to do an accurate legal and technical assessment of US 12,104,184.
  • Any attempt to infer scope from the number alone would produce non-actionable or potentially incorrect conclusions, which the operating constraints prohibit.

FAQs

  1. Can US 12,104,184 be analyzed without the claim text?
    Not in a way that supports legal-grade scope, infringement, or validity conclusions.

  2. What inputs are mandatory for a credible patent landscape analysis?
    Patent bibliographic data (assignee, priority, publication numbers), CPC/IPC classes, and the full claim set plus specification support.

  3. What makes claim construction decisive for infringement risk?
    The exact limitations, whether they are structural, functional, or process-based, and how terms are anchored to the specification.

  4. How is novelty vs obviousness usually determined in US patents?
    By mapping prior art references to each claim element and assessing whether a single reference anticipates or whether multiple references combine to render the claim obvious.

  5. How do continuations and family members change the landscape impact?
    They can broaden or narrow protection, affect priority, and shift validity and licensing dynamics.


References

[1] United States Patent 12,104,184. (Bibliographic record and full text not provided in the prompt.)

More… ↓

⤷  Start Trial

Details for Patent 12,104,184

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Akorn, Inc. HYDASE hyaluronidase Injection 021716 October 25, 2005 12,104,184 2042-12-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.